248 related articles for article (PubMed ID: 20358432)
1. Statistical characteristics of moxifloxacin-induced QTc effect.
Yan LK; Zhang J; Ng MJ; Dang Q
J Biopharm Stat; 2010 May; 20(3):497-507. PubMed ID: 20358432
[TBL] [Abstract][Full Text] [Related]
2. Statistical consideration in testing for assay sensitivity in a "thorough" QT study.
Sethuraman V; Wu S; Wang J
J Biopharm Stat; 2010 May; 20(3):641-53. PubMed ID: 20358442
[TBL] [Abstract][Full Text] [Related]
3. Sugammadex is not associated with QT/QTc prolongation: methodology aspects of an intravenous moxifloxacin-controlled thorough QT study.
de Kam PJ; van Kuijk J; Smeets J; Thomsen T; Peeters P
Int J Clin Pharmacol Ther; 2012 Aug; 50(8):595-604. PubMed ID: 22735462
[TBL] [Abstract][Full Text] [Related]
4. Effect of levetiracetam on cardiac repolarization in healthy subjects: a single-dose, randomized, placebo- and active-controlled, four-way crossover study.
Hulhoven R; Rosillon D; Bridson WE; Meeus MA; Salas E; Stockis A
Clin Ther; 2008 Feb; 30(2):260-70. PubMed ID: 18343264
[TBL] [Abstract][Full Text] [Related]
5. Population pharmacokinetic and concentration--QTc models for moxifloxacin: pooled analysis of 20 thorough QT studies.
Florian JA; Tornøe CW; Brundage R; Parekh A; Garnett CE
J Clin Pharmacol; 2011 Aug; 51(8):1152-62. PubMed ID: 21228407
[TBL] [Abstract][Full Text] [Related]
6. Lack of effect of aprepitant or its prodrug fosaprepitant on QTc intervals in healthy subjects.
Marbury TC; Jin B; Panebianco D; Murphy MG; Sun H; Evans JK; Han TH; Constanzer ML; Dru J; Shadle CR
Anesth Analg; 2009 Aug; 109(2):418-25. PubMed ID: 19608812
[TBL] [Abstract][Full Text] [Related]
7. Application of a probabilistic method for the determination of drug-induced QT prolongation in telemetered cynomolgus monkeys: effects of moxifloxacin.
Holzgrefe HH; Cavero I; Buchanan LV; Gill MW; Durham SK
J Pharmacol Toxicol Methods; 2007; 55(3):227-37. PubMed ID: 17097307
[TBL] [Abstract][Full Text] [Related]
8. A statistical assessment of QT data following placebo and moxifloxacin dosing in thorough QT studies.
Stylianou A; Roger J; Stephens K
J Biopharm Stat; 2008; 18(3):502-16. PubMed ID: 18470759
[TBL] [Abstract][Full Text] [Related]
9. Period correction of the QTc of moxifloxacin with multiple predose baseline ECGs is the least variable of 4 methods tested.
Zhang X; Silkey M; Schumacher M; Wang L; Raval H; Caulfield JP
J Clin Pharmacol; 2009 May; 49(5):534-9. PubMed ID: 19287043
[TBL] [Abstract][Full Text] [Related]
10. A single-dose, crossover, placebo- and moxifloxacin-controlled study to assess the effects of neratinib (HKI-272) on cardiac repolarization in healthy adult subjects.
Hug B; Abbas R; Leister C; Burns J; Sonnichsen D
Clin Cancer Res; 2010 Aug; 16(15):4016-23. PubMed ID: 20647478
[TBL] [Abstract][Full Text] [Related]
11. Reevaluation of moxifloxacin pharmacokinetics and their direct effect on the QT interval.
Grosjean P; Urien S
J Clin Pharmacol; 2012 Mar; 52(3):329-38. PubMed ID: 21415283
[TBL] [Abstract][Full Text] [Related]
12. Improving the precision of QT measurements.
Darpo B; Fossa AA; Couderc JP; Zhou M; Schreyer A; Ticktin M; Zapesochny A
Cardiol J; 2011; 18(4):401-10. PubMed ID: 21769821
[TBL] [Abstract][Full Text] [Related]
13. Pharmacokinetics and pharmacodynamics of three moxifloxacin dosage forms: implications for blinding in active-controlled cardiac repolarization studies.
Mason JW; Florian JA; Garnett CE; Moon TE; Selness DS; Spaulding RR
J Clin Pharmacol; 2010 Nov; 50(11):1249-59. PubMed ID: 20145260
[TBL] [Abstract][Full Text] [Related]
14. Effects of sugammadex doses up to 32 mg/kg alone or in combination with rocuronium or vecuronium on QTc prolongation: a thorough QTc study.
de Kam PJ; van Kuijk J; Prohn M; Thomsen T; Peeters P
Clin Drug Investig; 2010; 30(9):599-611. PubMed ID: 20568829
[TBL] [Abstract][Full Text] [Related]
15. Cardiac repolarization with Gabapentin enacarbil in a randomized, double-blind, placebo- and active-controlled, crossover thorough QT/QTc study in healthy adults.
Davy M; Upward J; Arumugham T; Twomey C; Chen C; Stier B
Clin Ther; 2013 Dec; 35(12):1964-74. PubMed ID: 24290737
[TBL] [Abstract][Full Text] [Related]
16. Evaluation of the effect of Naloxegol on cardiac repolarization: a randomized, placebo- and positive-controlled crossover thorough QT/QTc study in healthy volunteers.
Gottfridsson C; Carlson G; Lappalainen J; Sostek M
Clin Ther; 2013 Dec; 35(12):1876-83. PubMed ID: 24238792
[TBL] [Abstract][Full Text] [Related]
17. The use of beat-to-beat electrocardiogram analysis to distinguish QT/QTc interval changes caused by moxifloxacin from those caused by vardenafil.
Fossa AA; Langdon G; Couderc JP; Zhou M; Darpo B; Wilson F; Wallis R; Davis JD
Clin Pharmacol Ther; 2011 Sep; 90(3):449-54. PubMed ID: 21814193
[TBL] [Abstract][Full Text] [Related]
18. The effect of moxifloxacin on QTc and implications for the design of thorough QT studies.
Bloomfield DM; Kost JT; Ghosh K; Hreniuk D; Hickey LA; Guitierrez MJ; Gottesdiener K; Wagner JA
Clin Pharmacol Ther; 2008 Oct; 84(4):475-80. PubMed ID: 19238652
[TBL] [Abstract][Full Text] [Related]
19. Ritonavir 100 mg does not cause QTc prolongation in healthy subjects: a possible role as CYP3A inhibitor in thorough QTc studies.
Sarapa N; Nickens DJ; Raber SR; Reynolds RR; Amantea MA
Clin Pharmacol Ther; 2008 Jan; 83(1):153-9. PubMed ID: 17581594
[TBL] [Abstract][Full Text] [Related]
20. Effect of nalmefene 20 and 80 mg on the corrected QT interval and T-wave morphology: a randomized, double-blind, parallel-group, placebo- and moxifloxacin-controlled, single-centre study.
Matz J; Graff C; Vainio PJ; Kallio A; Højer AM; Struijk JJ; Kanters JK; Andersen MP; Toft E
Clin Drug Investig; 2011 Nov; 31(11):799-811. PubMed ID: 21967071
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
